Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

130.81 -3.25 (-2.42%)

Streaming Delayed Price Updated: 3:31 PM EDT, May 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

73 74 Next >

Evaluating Gilead Sciences: Insights From 15 Financial Analysts ↗

October 21, 2024

Via Benzinga

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

October 19, 2024

From Gilead Sciences, Inc.

Via Business Wire

After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment ↗

October 18, 2024

Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory results from the TROPiCS-04 study. However, the decision does not impact...

Via Benzinga

Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

October 17, 2024

Via Benzinga

Will GILEAD SCIENCES INC breakout? ↗

October 14, 2024

Technical Signals Point to a Possible Breakout for GILEAD SCIENCES INC.

Via Chartmill

Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights ↗

October 04, 2024

Via Benzinga

$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today ↗

October 01, 2024

Via Benzinga

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

October 17, 2024

Via Benzinga

Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

October 09, 2024

From Gilead Sciences, Inc.

Via Business Wire

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗

October 09, 2024

The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...

Via Benzinga

Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

October 09, 2024

From Gilead Sciences, Inc.

Via Business Wire

News Is Noise ↗

September 23, 2024

Via Talk Markets

Biotech Stocks Poised For Another Big Move In Q4 ↗

October 07, 2024

The healthcare sector can be a safe haven if volatility increases.

Via Talk Markets

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference

October 07, 2024

From Gilead Sciences, Inc.

Via Business Wire

S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion' ↗

October 07, 2024

Goldman Sachs raises S&P 500's EPS forecast to $268 in 2025, driven by AI tech demand & semiconductor recovery. Margin expansion & macro growth fuel optimism for tech & healthcare sectors.

Via Benzinga

Topics Artificial Intelligence Stocks

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

October 07, 2024

Via Benzinga

Gilead Sciences Unusual Options Activity For September 20 ↗

September 20, 2024

Via Benzinga

$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today ↗

September 13, 2024

Via Benzinga

Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries

October 02, 2024

From Gilead Sciences, Inc.

Via Business Wire

Top 4 Health Care Stocks That May Keep You Up At Night ↗

September 24, 2024

Via Benzinga

Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles ↗

September 23, 2024

Gilead Sciences has recalled one lot of its COVID-19 treatment, Veklury (remdesivir), due to glass particles found in vials. Gilead is notifying distributors to cease use and return the remaining...

Via Benzinga

Topics Product Recall

Biotech Boom Ahead? Key Stocks and ETFs to Watch Now

September 23, 2024

The Federal Reserve's recent 50bps rate cut could significantly boost biotech companies by lowering borrowing costs and improving access to capital.

Via MarketBeat

Topics ETFs Economy

AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug ↗

September 23, 2024

The company is still discussing the future for its Daiichi Sankyo-partnered ADC in metastatic breast cancer treatment.

Via Investor's Business Daily

3 Dirt Cheap Stocks to Buy Right Now ↗

September 21, 2024

Bargain hunters should love these great stocks.

Via The Motley Fool

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields ↗

September 20, 2024

Via Benzinga

Got $200? 2 Healthcare Stocks to Buy and Hold Forever ↗

September 14, 2024

These two stocks have had their issues in recent years, but both look like reliable long-term bets.

Via The Motley Fool

Time To Invest And Or Trade In Bio-Tech Stocks? ↗

September 13, 2024

Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...

Via Talk Markets

Topics ETFs

Why Gilead Sciences Stock Thrashed the Market Today ↗

September 12, 2024

In drug development, solid performance in large-scale clinical trials is crucial.

Via The Motley Fool

Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections ↗

September 12, 2024

Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, outperforming once-daily Truvada. Global regulatory filings are expected by...

Via Benzinga

Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention ↗

September 12, 2024

The company is trying to get ahead of a patent expiration for one of its key HIV prevention drugs.

Via Investor's Business Daily

Topics Intellectual Property

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

73 74 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.